In particular, SGLT2 inhibitors, the most recent class of drugs, are associated with a variety of pleiotropic effects that ensure nephroprotection and cardioprotection, regardless of co-affliction with diabetes mellitus. Here, SLC5A2 is linked to diabetes mellitus.